Prognostic value of DNMT3A mutations in myelodysplastic syndromes: a meta-analysis

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• Mutations in the DNA (cytosine-5)-methyltransferase 3 alpha (DNMT3A) gene are frequently observed in MDS.
• The prognostic value of DNMT3A mutations in MDS remains a subject of debate.

Purpose of the Study:

• To conduct a meta-analysis to clarify the prognostic significance of DNMT3A mutations in patients with MDS.
• To evaluate the impact of DNMT3A mutations on overall survival (OS) and leukemia-free survival (LFS) in MDS.

Main Methods:

• Systematic literature search of major databases including PubMed, Embase, Web of Science, Clinical Trials, and Cochrane Library.
• Inclusion of 12 studies comprising 2236 MDS patients.
• Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to assess survival outcomes.

Main Results:

• MDS patients with DNMT3A mutations exhibited significantly poorer overall survival (OS: HR = 1.654, p < 0.001).
• DNMT3A mutations were associated with significantly worse leukemia-free survival (LFS: HR = 4.624, p < 0.001).
• The findings were consistent across the included studies.

Conclusions:

• This meta-analysis demonstrates that DNMT3A mutations have an adverse prognostic effect in patients with MDS.
• Identifying DNMT3A mutations can aid in more accurate risk stratification and prognostic assessment for MDS patients.
• These findings support the clinical utility of genetic profiling in managing MDS.